Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
A phase 3 trial of Hernexeos in adjuvant HER2m NSCLC is planned.
The group’s $8bn acquisition of Merus was the standout in the third quarter.
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
Key FDA decisions are expected to face delays.
New trial starts include MediLink's 12th clinical-stage Tmalin candidate.
After trimming its cell therapy pipeline last year, the group is now out entirely.
